Related Experiment Video
Updated: May 16, 2025
Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
Published on: November 1, 2017
Engineered cell nanovesicle antagonists for androgen deprivation therapy of melanoma
Yu Zhao1, Yichuan Ma2, Qingqing Leng1
1College of Pharmaceutical Science, Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Hebei University, Baoding 071002, China; State Key Laboratory of New Pharmaceutical Preparations and Excipients, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, Baoding 071002, China.
Abstract:
Epidemiological studies on melanoma have revealed significant gender disparities, with the incidence and mortality rates being higher in males than in females. Recent studies indicate that androgen contributing to T cell exhaustion and promoting cancer cell proliferation. While clinical androgen deprivation therapies (ADT),particularly the use of androgen receptor (AR) antagonists to block AR signaling, has been employed in clinical settings to reduce androgen levels, antiandrogen drugs often encounter challenges such as poor targeting and selectivity, increased toxicity, low stability, short half-life and the emergence of drug resistance. Here, we establish a nanoantagonists for efficient AR signaling blockade by arming antigen-activated dendritic cells (DCs) nanovesicles with AR antibodies (aAR-NVOVA). This innovative approach demonstrates dual therapeutic efficacy: aAR-NVOVA effectively disrupts androgen-AR interactions in both melanoma cells and T cells, simultaneously inhibiting tumor proliferation and reversing T cell exhaustion. Furthermore, aAR-NVOVA retains the inherent immunostimulatory properties of DCs, facilitating T cell activation and enhancing cytotoxic T lymphocyte infiltration within tumor tissues. As a result, a synergistic effect has been observed in boosting T cell-based immunotherapy by simultaneously enhancing T cell activity and reducing its exhaustion. Our study using aAR-NVOVA to antagonize androgen effects offers a promising new strategy for enhancing melanoma immunotherapy.
Insights
This study introduces novel nanovesicles targeting androgen receptor signaling to combat melanoma. This approach inhibits tumor growth and enhances T cell immunotherapy by reducing exhaustion.
Area of Science:
- Oncology
- Immunology
- Nanotechnology
Background:
- Melanoma exhibits gender disparities, with higher incidence and mortality in males.
- Androgen signaling promotes melanoma cell proliferation and T cell exhaustion.
- Current androgen deprivation therapies face challenges like poor targeting and drug resistance.
Purpose of the Study:
- To develop a targeted nanovesicle system for efficient androgen receptor (AR) signaling blockade in melanoma.
- To investigate the dual therapeutic efficacy of these nanovesicles in inhibiting tumor growth and reversing T cell exhaustion.
- To enhance T cell-based immunotherapy for melanoma.
Main Methods:
- Engineered nanovesicles (aAR-NVOVA) armed with AR antibodies, derived from antigen-activated dendritic cells (DCs).
- Utilized nanovesicles to disrupt androgen-AR interactions in melanoma cells and T cells.
- Assessed the impact on tumor proliferation, T cell exhaustion, and T cell-mediated anti-tumor immunity.
Main Results:
- aAR-NVOVA effectively blocked AR signaling in both melanoma and T cells.
- Demonstrated dual efficacy: inhibition of tumor proliferation and reversal of T cell exhaustion.
- Enhanced T cell activation, cytotoxic T lymphocyte infiltration, and synergistic effects in immunotherapy.
Conclusions:
- aAR-NVOVA represents a promising strategy for melanoma immunotherapy by antagonizing androgen effects.
- This approach offers a novel method to enhance T cell activity and overcome T cell exhaustion.
- The dual-action nanovesicles improve melanoma treatment outcomes by combining direct anti-tumor effects with immune system modulation.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy